Beaverton Patient Gains Coverage for Cancer Treatment
Niki Taylo will begin her first round of ENHERTU treatment after the insurer approved her request.
Updated on Oct. 16, 2026 in Cancer
After two initial denials, Beaverton resident Niki Taylo has secured coverage for her ENHERTU cancer treatment. The medication, which costs $63,000 every three weeks, was approved following a community email campaign and a formal third-party appeal.
Why it matters
The oncologist recommended this specific drug to target cancer cells after standard chemotherapy failed to stop tumor growth in Taylo's Stage IV endometrial cancer. Securing insurance coverage ensures the patient can access critical therapy without relying solely on private donations.
The prescribed ENHERTU regimen requires administration every three weeks at a cost of $63,000. Prior to this coverage approval, the patient faced two formal denials from her insurance provider.
The players
Niki Taylo
She is a Beaverton resident diagnosed with Stage IV endometrial cancer who advocated for her own medical coverage.
Regence Blue Cross Blue Shield
This is the health insurance provider that initially denied coverage for the patient before ultimately approving the treatment.
The details
Following her 2024 diagnosis, Taylo launched a successful fundraiser that surpassed its $75,000 goal in one week. While the insurance provider has now agreed to cover the medication, the family plans to maintain their raised funds to pursue additional care options outside the United States.
Timeline
Niki Taylo was diagnosed with endometrial cancer in 2024.
The community fundraiser reached its $75,000 goal in October 2026.
Regence Blue Cross Blue Shield confirmed the coverage decision on October 16, 2026.
Taylo received official notification of the ENHERTU4 program coverage on October 16, 2026.
The patient is scheduled to begin her first round of treatment on October 17, 2026.
The Big Picture
This case underscores how patients leverage mandated appeal processes under the Patient Protection and Affordable Care Act's external appeals framework to secure coverage for high-cost therapies. The successful challenge illustrates the critical role of formal appeals when standard insurance coverage is denied.
This outcome provides a pathway for patients to challenge high-cost treatment denials through persistent administrative appeals. It highlights the potential for community support and formal advocacy to change insurance outcomes for critical life-saving medications.
The takeaway
Patients facing high-cost drug denials can effectively utilize third-party appeal processes to challenge insurance company decisions. Utilizing community support can provide a necessary financial buffer while navigating the complexities of medical coverage and authorization.
Further reading
Learn more about the latest developments in local oncology care at the Cancer section.
Source note: This article includes information reported by KPTV.
